retatrutide glp-1 gip glucagon receptor agonist Retatrutide, a GIP, and agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide: The "Triple G" Peptide

The ideal dose for an individual depends on weight loss goals, underlying health conditions and how your body reacts to the treatment

Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease

At that point, if theyd like to proceed with the GLP1 and they meet criteria, then we roll with it and we consider it harm reduction

These medications help regulate appetite and blood sugar, leading to significant weight loss when combined with lifestyle changes

Everything below reflects research-trial dosing, not a clinic prescription

Some individuals experienced dramatic improvements with lower amounts